Literature DB >> 11003474

Bacterial lipoprotein based expression vectors as tools for the characterisation of African swine fever virus (ASFV) antigens.

A Leitão1, A Malur, C Cartaxeiro, G Vasco, B Cruz, P Cornelis, C L Martins.   

Abstract

African swine fever virus (ASFV) is the causative agent of an important pig disease for which protective mechanisms are still poorly understood. The present work was aimed at the characterisation of ASFV antigens using previously reported vectors that allow their expression as fusion proteins with the bacterial lipoprotein OprI. Several recombinant clones induced SLA-restricted, ASFV-specific lymphoproliferation and one (A2) was demonstrated to stimulate ASFV-specific CTL activity in vitro, in opposition to the effect of UV inactivated virus. The nucleotide sequence of the fragment cloned in A2 showed 99% identity with a portion of the G1340L ORF of the BA71V isolate, and the expressed fusion lipoprotein induced specific antibodies in vivo. Blood mononuclear leukocytes from a pig immunised with outer membrane preparations from A2 showed to reduce strongly (99.6%) the ASFV yield in cultures of autologous macrophages. However, after inoculation with virulent virus the pig developed acute fatal ASF. Overall our results show that OprI based expression vectors are valuable tools to screen viral antigens in terms of their capacity to trigger immune competent cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003474     DOI: 10.1007/s007050070081

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  9 in total

Review 1.  African swine fever vaccines: a promising work still in progress.

Authors:  Laia Bosch-Camós; Elisabeth López; Fernando Rodriguez
Journal:  Porcine Health Manag       Date:  2020-07-02

2.  Identification and Immunogenicity of African Swine Fever Virus Antigens.

Authors:  Christopher L Netherton; Lynnette C Goatley; Ana Luisa Reis; Raquel Portugal; Rachel H Nash; Sophie B Morgan; Lynden Gault; Raquel Nieto; Veronica Norlin; Carmina Gallardo; Chak-Sum Ho; Pedro J Sánchez-Cordón; Geraldine Taylor; Linda K Dixon
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 3.  Adaptive Cellular Immunity against African Swine Fever Virus Infections.

Authors:  Alexander Schäfer; Giulia Franzoni; Christopher L Netherton; Luise Hartmann; Sandra Blome; Ulrike Blohm
Journal:  Pathogens       Date:  2022-02-20

Review 4.  African swine fever control and prevention: an update on vaccine development.

Authors:  Ana Catarina Urbano; Fernando Ferreira
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 5.  African Swine Fever Virus: A Review.

Authors:  Zhaoyao Li; Wenxian Chen; Zilong Qiu; Yuwan Li; Jindai Fan; Keke Wu; Xiaowen Li; Mingqiu Zhao; Hongxing Ding; Shuangqi Fan; Jinding Chen
Journal:  Life (Basel)       Date:  2022-08-17

6.  The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNalpha, TNFalpha and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60.

Authors:  S Gil; N Sepúlveda; E Albina; A Leitão; C Martins
Journal:  Arch Virol       Date:  2008-09-12       Impact factor: 2.574

Review 7.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

Review 8.  Approaches and Perspectives for Development of African Swine Fever Virus Vaccines.

Authors:  Marisa Arias; Ana de la Torre; Linda Dixon; Carmina Gallardo; Ferran Jori; Alberto Laddomada; Carlos Martins; R Michael Parkhouse; Yolanda Revilla; Fernando And Jose-Manuel Rodriguez
Journal:  Vaccines (Basel)       Date:  2017-10-07

9.  Antigenic and immunogenic properties of recombinant proteins consisting of two immunodominant African swine fever virus proteins fused with bacterial lipoprotein OprI.

Authors:  Guanglei Zhang; Wei Liu; Zhan Gao; Yanyan Chang; Sicheng Yang; Qian Peng; Sudan Ge; Bijing Kang; Junjun Shao; Huiyun Chang
Journal:  Virol J       Date:  2022-01-21       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.